Kouvelos George N, Oikonomou Kyriakos, Antoniou George A, Verhoeven Eric L G, Katsargyris Athanasios
1 Department of Vascular and Endovascular Surgery, Paracelsus Medical University Nuremberg, Germany.
2 Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute Hospitals NHS Trust, Manchester, UK.
J Endovasc Ther. 2017 Feb;24(1):59-67. doi: 10.1177/1526602816673325. Epub 2016 Oct 10.
To provide an updated systematic literature review and summarize current evidence on proximal aortic neck dilatation (AND) after endovascular aneurysm repair (EVAR).
A review of the English-language medical literature from 1991 to 2015 was conducted using MEDLINE and EMBASE to identify studies reporting AND after EVAR. Studies considered for inclusion and full-text review fulfilled the following criteria: (1) reported AND after EVAR, (2) included at least 5 patients, and (3) provided data on AND quantification. The search identified 26 articles published between 1998 and 2015 that encompassed 9721 patients (median age 71.8 years; 9439 men).
AND occurred in 24.6% of patients (95% CI 18.6% to 31.8%) over a period ranging from 15 months to 9 years after EVAR. No significant dilatation of the suprarenal part of the aorta was reported by most studies. The incidence of combined clinical events (endoleak type I, migration, reintervention during follow-up) was higher in the AND group (26%) when compared with 2% in the group without AND (OR 28.7, 95% CI 5.43 to 151.67, p<0.001).
AND affects a considerable proportion of EVAR patients and was related to worse clinical outcome, as indicated by increased rates of type I endoleak, migration, and reinterventions. Future studies should focus on a better understanding of the pathophysiology, predictors, and risk factors of AND, which could identify patients who may warrant a different EVAR strategy and/or a closer post-EVAR surveillance strategy.
提供最新的系统文献综述,并总结关于血管内动脉瘤修复术(EVAR)后近端主动脉颈部扩张(AND)的现有证据。
使用MEDLINE和EMBASE对1991年至2015年的英文医学文献进行综述,以确定报告EVAR后AND的研究。纳入考虑和全文审查的研究符合以下标准:(1)报告EVAR后的AND;(2)至少纳入5例患者;(3)提供AND量化数据。检索确定了1998年至2015年发表的26篇文章,涵盖9721例患者(中位年龄71.8岁;9439例男性)。
在EVAR后15个月至9年的时间段内,24.6%的患者发生了AND(95%可信区间18.6%至31.8%)。大多数研究未报告主动脉肾上腺部分有明显扩张。AND组的联合临床事件(I型内漏、移位、随访期间再次干预)发生率(26%)高于无AND组(2%)(比值比28.7,95%可信区间5.43至151.67,p<0.001)。
AND影响相当一部分EVAR患者,且与较差的临床结局相关,I型内漏、移位和再次干预的发生率增加表明了这一点。未来的研究应集中在更好地理解AND的病理生理学、预测因素和危险因素,这可能识别出可能需要不同EVAR策略和/或更密切的EVAR后监测策略的患者。